On Thursday, drugmaker Wyeth
After adjusting for non-routine items, the company reported a 7% spike in earnings per share on a 9% increase in net revenue compared with a year ago. There was a 4% increase in net revenue from the company's top-selling drug, the anti-depressant Effexor. More impressive were the Nos. 2 and 3 sellers, Prevnar and Enbrel. Net revenue for Prevnar, a vaccine for infants, grew by 24%. For Enbrel, a medication for inflammatory diseases including rheumatoid arthritis that Wyeth markets with Amgen
Revenue grew for all three of Wyeth's businesses, including 11% in its animal health business. Wyeth is not the only large-cap pharmaceutical company experiencing an improvement in that business. On Wednesday, Pfizer
These strong results by Wyeth, coupled with a reasonable valuation of its common stock, enabled it to increase its share repurchase authorization to $5 billion. This move toward buying back depressed shares is similar to one Johnson & Johnson
Wyeth continues to be one of big pharma's most reliable performers from an operations standpoint, and the latest quarter is an outstanding example of its consistency.
For related Foolishness: